Aeterna Zentaris to Make Poster and Oral Presentations on Highly Selective Erk Inhibitor Compound, AEZS-131, at Major Cancer Conference in Boston

QUEBEC CITY, Oct. 26 /PRNewswire/ -- Aeterna Zentaris Inc. , today announced that it will make a poster presentation, as well as an oral presentation on preclinical results for AEZS-131, a leading highly selective Erk inhibitor, which support its further evaluation as a potential anticancer compound in monotherapy or in combination with PI3K/Akt pathway inhibitors. Both presentations will be made during the Cambridge Healthtech Institute's 8th International "Discovery on Target" Conference, to be held November 2-4, 2010, in Boston, Massachusetts.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit http://www.aezsinc.com/.

AETERNA ZENTARIS INC.

CONTACT:

Investor Relations
Ginette Vallieres

Investor Relations Coordinator
[phone] ext. 265
href="mailto:[e-mail]">[e-mail]


Media Relations
Paul Burroughs
Director of
Communications
[phone] ext. 406
href="mailto:[e-mail]">[e-mail]